New approaches for temozolomide therapy: use in newly diagnosed glioma

Détails

ID Serval
serval:BIB_B8017927CC8F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
New approaches for temozolomide therapy: use in newly diagnosed glioma
Périodique
Seminars in Oncology
Auteur⸱e⸱s
Stupp  R., Newlands  E.
ISSN
0093-7754 (Print)
Statut éditorial
Publié
Date de publication
08/2001
Volume
28
Numéro
4 Suppl 13
Pages
19-23
Notes
Journal Article
Review --- Old month value: Aug
Résumé
Temozolomide is a novel oral alkylating agent that has been approved for the treatment of patients with refractory malignant glioma. Treatment with temozolomide is now being explored in patients with newly diagnosed malignant glioma in several ongoing clinical trials, and alternative treatment schedules are being evaluated. A schedule of continuous daily treatment with temozolomide for 6 or 7 weeks has been developed and determined to be safe, effective, and well tolerated. When temozolomide was continuously given along with a standard course of radiation therapy for 6 or 7 weeks, followed by adjuvant treatment with temozolomide, promising preliminary results were seen in patients with malignant gliomas.
Mots-clé
Antineoplastic Agents, Alkylating/administration & dosage/*therapeutic use Central Nervous System Neoplasms/*drug therapy/radiotherapy Chemotherapy, Adjuvant Clinical Trials Dacarbazine/administration & dosage/analogs & derivatives/*therapeutic use Drug Administration Schedule Glioma/*drug therapy/radiotherapy Humans Quality of Life
Pubmed
Web of science
Création de la notice
28/01/2008 8:39
Dernière modification de la notice
20/08/2019 15:26
Données d'usage